Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 11;17(8):e0272301.
doi: 10.1371/journal.pone.0272301. eCollection 2022.

Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration

Semra Ozdemir  1   2 , Eric Finkelstein  1   2   3 , Jia Jia Lee  1 , Issac Horng Khit Too  4 , Kelvin Yi Chong Teo  5   6 , Anna Chen Sim Tan  5   6 , Tien Yin Wong  5   6 , Gemmy Chui Ming Cheung  5   6
Affiliations

Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration

Semra Ozdemir et al. PLoS One. .

Abstract

Purpose: (1) To investigate the relative importance of convenience (consultation frequency and injection frequency) against treatment outcomes (visual and anatomical outcomes) and out-of-pocket medical costs via a discrete choice experiment (DCE), and (2) to investigate how patient characteristics affect patient treatment preferences.

Methods: Eligibility criteria were: (1) receiving a neovascular age-related macular degeneration (nAMD) diagnosis; (2) receiving anti-VEGF treatment; (3) being ≥21 years old, and (4) being able to speak and understand English/Mandarin. Patients were presented with eight choice tasks and asked to choose between their current treatment and two hypothetical treatments that varied by six attributes: number of clinic visits in a year, number of injections in a year, vision quality, control of swelling in retina, drug labelling and out-of-pocket cost.

Results: This analysis involved 180 patients. Based on latent class logistic regressions, vision quality was the most important attribute (34%) followed by cost (24%). The frequency of total clinic visits (15%) was the third most-important attribute, closely followed by labelling (12%) and control of retina swelling (11%). Injection frequency was the least important attribute (4%).

Conclusions: Vision quality was the most important attribute followed by the out-of-pocket costs. Given the same outcomes, patients preferred treatment regimens which require fewer total clinic visits. In comparison, injection frequency alone did not influence patient preferences. With increasing treatment options for nAMD, understanding patients' preferences can help clinicians in selecting agents and treatment regimen most preferred for each patient, which may lead to improved long-term adherence and outcomes.

PubMed Disclaimer

Conflict of interest statement

Semra Ozdemir, Anna Cheng Sim Tan, Kelvin Yi Chong Teo, Tien Yin Wong and Gemmy Chui Ming Cheung reported receiving grants from Novartis during the conduct of the study. Issac Horng Khit Too is being employed by Novartis. Eric Finkelstein and Jia Jia Lee reported no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Recruitment flowchart.
Fig 2
Fig 2. Sample choice task.
Fig 3
Fig 3. Relative attribute importance (out of 100%) for Class 1, Class 2, and overall sample.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Steinmetz JD, Bourne RR, Briant PS, Flaxman SR, Taylor HR, Jonas JB, et al.. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet Global Health. 2021;9(2):e144–e60. doi: 10.1016/S2214-109X(20)30489-7 - DOI - PMC - PubMed
    1. Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al.. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014;2(2):e106–e16. doi: 10.1016/S2214-109X(13)70145-1 - DOI - PubMed
    1. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. The Lancet. 2018;392(10153):1147–59. - PubMed
    1. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65. e5. doi: 10.1016/j.ophtha.2008.10.018 - DOI - PubMed
    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al.. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1419–31. doi: 10.1056/NEJMoa054481 - DOI - PubMed

Publication types

Substances